China's pharmaceutical product imports have generally shown an upward trend from 2013 to 2023, reaching 183.61 thousand metric tons in 2023. After an initial drop in 2015, imports have steadily increased, reflecting the growing demand. The compound annual growth rate (CAGR) over the past five years was 3.75%. The year-on-year changes have been variable, with a notable dip in 2022 followed by a mild recovery in 2023.
Looking ahead, forecasted data up to 2028 suggest continued growth, albeit at a slower CAGR of 2.35%. By 2028, imports are expected to reach 214.56 thousand metric tons, reflecting a cumulative growth rate of 12.3% over the next five years. This slower growth rate might indicate market maturation or increased local production.
Future trends to watch for include:
- Monitoring the impact of local pharmaceutical production capabilities on import demands.
- Changes in healthcare policies and regulations that could affect import levels.
- Technological advancements in pharmaceutical production and their adoption within China.
- Economic factors that might influence healthcare spending and import levels.
